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Abstract PLC activity was stimulated either by 1-100/xM of 
GTP or by 100-3,000 /~M Ca 2+ in lysed synaptosomal mem- 
branes of the guinea pig cerebellum. The Jc-opioid receptor ag- 
onist selectively inhibited the PLC activity stimulated by 100/tM 
GTP, but not by 100-3,000 /tM Ca 2+. Pretreatment of mem- 
branes with PTX abolished such a ~¢-agonist-induced inhibition 
of PLC activity. The reconstitution of Gil, but not of Go purified 
from porcine brains with PTX-treated membranes showed a com- 
plete recovery of the i¢-agonist-inhibition of PLC activity. These 
findings suggest hat a novel subtype K-receptor mediates inhibi- 
tion of PLC through inhibiting the intrinsic activity of PTX- 
substrate G-proteins. 
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I. Introduction 
Several different hormones and neurotransmitters influence 
phosphatidylinositol metabolism, in various tissues [1]. Dia- 
cylglycerol and inositol 1,4,5-trisphosphate (InsP3), both de- 
rived from the hydrolysis of phosphatidylinositol 4,5-bis- 
phosphate (PIP2) by phosphatidylinositol-specific phospholip- 
ase C (PLC) serve as important intracellular second messengers 
for protein kinase C activation [2] and intracellular Ca 2+ mobi- 
lization [1]. Thus, it has been widely accepted that the receptor- 
linked regulation of PLC activity is one of major transduction 
pathways which communicate extracellular signals to intracel- 
lular second messengers. 
There is accumulating evidence that pertussis toxin (PTX)- 
sensitive GTP-binding proteins (G-proteins) are involved in the 
regulation of PLC activity in several receptor mechanisms [3], 
as well as PTX-insensitive ones, such as Gq [1]. In some cells 
the receptor-mediated stimulation of PLC was abolished by 
PTX [4-6], while in other cells there were no changes in PLC 
activations by such treatments [7,8]. We have reported that the 
receptor-mediated stimulation of PLC in rat brain synaptic 
membranes was abolished by PTX pretreatment and recovered 
by reconstitution with purified Gil, but not with Go [9]. Most 
*Corresponding author. Fax: (81) (45) 785 3645. 
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recently we reported that ~-opioid receptor evoked a calcium- 
dependent chloride current hrough an activation of Gil and 
PLC in Xenopus oocytes [10,11]. 
On the other hand, some investigators eported the contra- 
dictory findings that the PLC activity is inhibited by various 
receptor stimulations. The receptor-mediated inhibition of PLC 
as a phenomena was first reported by Canonico et al. [12] for 
the D2 receptor in pituitary and followed up by several groups 
[13]. Most recently, we also found that the x-opioid agonist 
inhibited the GTP-stimulated PLC activity in synaptic mem- 
branes of the guinea pig cerebellum [14]. Of interest is the fact 
that in such preparations, the x-opioid agonist inhibits G-pro- 
tein activity [15,16]. As cloned opioid K-receptor [17,18] shows 
a stimulatory action on Gi coupled to inhibition of adenylate 
cyclase [19] and to PLC activation [11], the K-subtype to show 
an inhibition of G-protein activity should be of another sub- 
type. Here we report the involvement of PTX-sensitive G-pro- 
teins, such as Gil in such an inhibitory coupling between 
x-opioid receptor and PLC by reconstitution experiments. 
2. Materials and methods 
2.1. Materials 
U-50,488H was a gift from Upjohn, Japan. Pertussis toxin (PTX) was 
obtained from Funakoshi (Tokyo, Japan), D-myo-inositol 1,4,5-tris- 
phosphate (InsP3) 3H assay kit and [32p]NAD from Amersham, 
Japan. 
2.2. Membrane preparation 
Male guinea pig weighing 250-350 gwere decapitated. The cerebel- 
lum was dissected from the whole brain, homogenized in 10 vol. of 0.32 
M sucrose containing 5 mM HEPES, pH 7.5 (buffer A) and centrifuged 
at 1,000 × g for 10 min. The supernatant (S1) was further centrifuged 
at 15,000 ×g for 20 min to produce pellet (P2) and $2. The P2 was 
resuspended in 5 ml of buffer A, laid on Ficoll gradient (10 ml of 7.5% 
w/v and 10 ml of 12% w/v) and centrifuged at68,000 × g for 60 min [20]. 
Synaptosomes were recovered with a Pasteur pipette at the 7.5%/12% 
Ficoll interface. The synaptosomes were mixed with 9 vols. of 100 mM 
Na-phosphate, pH 7.5 (buffer B) and centrifuged at35,000 × g for 20 
rain. The pellet (synaptosomal lysed membranes) was washed once with 
buffer B and resuspended in the same buffer to make a protein concen- 
tration of 1~ mg/ml. All procedures were done at 4°C. 
2.3. Treatment of synaptic membranes with PTX 
Procedures ofpreactivation f PTX and ADP-ribosylation ofsynap- 
tic membranes by preactivated PTX were as described [9,21]. After 
treatment with PTX, the membranes were washed three times, and then 
suspended in buffer B. Radiolabeling of membrane proteins with 
[32p]NAD was carried out reported by Katada and Ui [22]. 
2.4. Reconstitution fGil or Go into PTX-treated membranes 
Gil or Go was purified (>95%) from cholate xtracts of porcine 
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brain membranes [23]. The PTX (10/.tg/ml)-treated membranes (10-20 
/tg of protein) was reconstituted with Gil or Go (0.25-4 pmol) by 
incubating at 4°C for 60 min in 20 ¢tl of buffer B. 
2.5. Phospholipase C assay 
Membrane PLC activity was determined by measuring InsP3 derived 
from endogenous membrane PIP2, using [3H]lnsP3 assay system 
(Amersham), according to Manufacturer's protocol. In standard exper- 
iments, the assay contained synaptosomal lysed membranes (10-20 ¢tg 
of protein) of guinea pig cerebellum, 1 mM ATE 100 ,uM GTP, 10 ,uM 
CaC12, 100 mM NaC1, 6 mM MgC12, 1 mM DTT in 200 ,ul of buffer 
B. The incubation was carried out for 2 min at 37°C, unless otherwise 
stated. The reaction was terminated with an equal volume of 15% (w/v) 
of ice-cold trichloroacetic a id. After 30 rain standing on ice, the reac- 
tion mixture was centrifuged at 35,000 x g for 10 min. Supernatants 
were extracted 3 times with 5 vol. of water-saturated diethyl ether. The 
aqueous phase was titrated to pH 7.5 with NaHCO3 and then kept at 
-20°C until the InsP3 assay. The InsP3 was stable for up to 2 weeks 
at -20°C and all assays were run in duplicate. InsP3 formation was 
calculated from the difference between InsP3 content at each incuba- 
tion time and that without incubation (0 time). Proteins were deter- 
mined by the method of Lowry et al. [24]. 
3. Resu l ts  
3.1. Characterization ofGTP-stimulation of lnsP3 accumulation 
in guinea pig cerebellar membranes 
When synaptosomal membranes were incubated with 100 
/zM GTP in the presence of 10/zM Ca 2÷, there was an immedi- 
ate increase in InsP3 accumulation. As shown in Fig. 1A, the 
increase in accumulation reached a plateau at 2 min after the 
initiation of incubation, while there was no increase in the 
absence of GTP. The InsP3 accumulation measured at 2 rain 
incubation increased as the concentrations of GTP up to 100 
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Fig. 1. Effects of the x-opioid agonist on InsP3 formation stimulated 
by GTP or Ca 2* in guinea pig cerebellar membranes. Measurement of
InsP3 accumulation was performed as described in section 2. Amounts 
of InsP3 accumulated for 2 min in Panel A, B and E are shown as 
pmol/mg protein, and those in panel C and D were as a% of the control 
without U-50,488H, respectively. Panel A: Time course of InsP3 accu- 
mulation in the presence or absence of 100 ,uM GTE Panel B: InsP3 
accumulation atvarious concentrations of GTP. Panel C: Time course 
of U-50,488H (100 nM)-induced inhibition of InsP3 accumulation i
the presence of 100 ¢tM GTP. Results represent the ratio of InsP3 
accumulation for various incubation times in the presence of 100 nM 
U-50488H to that in its absence (control) as a percentage. Panel D: 
InsP3 accumulation at various concentrations of U-50,488H in the 
presence of 100/IM GTP. Panel E: InsP3 accumulation at various 
concentrations of Ca 2+ in the presence or absence of 100 nM U- 
50,488H. Experiments were carried out in duplicate. Each point is the 
mean + S.E.M. from 3-5 separate xperiments. 
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Fig. 2. Abolition of the x-agonist-inhibition f PLC activity by PTX 
treatment of guinea pig cerebellar membranes. Measurement of InsP3 
accumulation and PTX-treatment of cerebellar membranes were as 
described in section 2. Membranes treated with vehicle or PTX (as 
indicated with underline in the figure), were incubated at 37°C for 
2 rain. The condition in each experiment was depicted in the figure, as 
the presence (+) and absence (-) of 100/ /M GTP and/or 100 nM 
U-50,488H. Each result represents the mean _+ S.E.M. of 3 separate 
experiments. *The difference is statistically significant (P<0.05, Stu- 
dent's t-test). 
~M (Fig. 1B). We obtained preliminary data that InsP3 binding 
protein in 'InsP3 assay kit' did not cross-react with 100 ~M 
GTP (data not shown). Such an increase in InsP3 accumulation 
was also observed with non-hydrolyzable GTP analogs, 
GppNHp and GTPTS, but not by other nucleotides uch as 
GDP, GMP, CDP and CTP (Table 1). In addition, we have 
previously reported that the GTP-stimulation of PLC was 
markedly reduced by the addition of neomycin, an inhibitor of 
phospholipase C or 0.2 mM EGTA to the assay mixture [14]. 
The calcium-dependent activation of PLC is consistent with 
findings of other investigators [7,8]. Thus, the membrane- 
bound PLC activity seems to be regulated by G-proteins. 
3.2. ~¢-Opioid receptor agonist inhibits the GTP-stimulated PLC 
activity 
In the guinea pig cerebellum, x-opioid receptors are predom- 
inant over / l -  and ~-receptors [25]. U-50,488H at 100 nM, a 
selective x-opioid receptor agonist [26], showed a complete 
inhibition of PLC in the presence of 100 ¢tM GTP and within 
5 rain (Fig. 1C), but not in the absence of GTP (data not 
shown). The x-agonist concentration-dependently inhibited 
GTP (100/IM)-stimulated PLC measured at 2 rain in ranges of 
1 100 nM (Fig. 1D). The maximal and half maximal inhibitory 
concentrations of U-50,488H were 100 nM and 65 nM, respec- 
tively. 
As shown in Fig. 1E, the PLC activity was also stimulated 
by the addition of millimolar ranges of Ca z+ in the absence of 
GTP, as noted by other workers [7,8]. The stimulation was 
much higher than that observed with GTP in the presence of 
10 ~M Ca 2÷. However, the x-agonist at 100 nM showed no 
significant change in PLC activity stimulated by Ca 2÷. 
3.3. Abolition of  the ~¢-agonist-induced inhibition of  
GTP-stimulation of  PLC by PTX and its recovery by 
reconstitution with purified Gil 
To further clarify the involvement of G-protein in the 
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Fig. 3. Recovery of the ~:-agonist-inhibition of PLC activity in PTX- 
treated membranes by reconstitution with purified Gil, Go or PTX- 
treated Gil. Data represnt percentage of control nsP3 accumulation 
in PTX-treated preparations. Reconstitution of purified Gil, Go or 
PTX-treated Gil was performed as described in section 2. Symbols 
represent data in preparations reconstituted with Gil (o), Go (D) and 
ADP-ribosylated Gil by PTX (©), respectively. All experiments pre- 
sented here were carried out in the presence of 100 nM U-50,488H and 
100/JM GTP. Each bar (in triplicate) represents he mean from 2 sep- 
arate experiments. There were no significant changes between both 
experiments. 
x-agonist-inhibition f GTP-stimulated PLC activity, the cere- 
bellar membranes were pretreated with preactivated PTX (10 
/~g/ml) at 37°C for 30 min. As shown in Fig. 2, the x-agonist- 
induced inhibition of PLC activity was abolished by PTX- 
treatment, while there was no change in the basal or GTP- 
stimulated activity of PLC between vehicle- and PTX-treated 
membranes. These findings are consistent with reported ata 
that the PTX abolished the ability of PTX-substrate G-pro- 
teins, such as Gi and Go to functionally couple to receptors 
[27], but shows no significant effect on the GTP),S binding 
activities [28]. 
To reconstitute purified G-proteins into PTX-treated mem- 
branes, the addition of detergents o the incubation mixture is 
required. When various detergents at 0.05% were added to the 
assay mixture, 3-[(3-cholamidopropyl)dimethylammonio]pro- 
panesulfonic acid/CHAPS, digitonin and Lubrol-PX reduced 
PLC activity in the presence of 100/.tM GTP to the level below 
10% of the control without detergents, while there was no 
inhibition with sodium cholate. Sodium cholate treatment in- 
creased the basal activity from 65 to 110 pmol/mg protein. 
Thus, we chose sodium cholate for reconstitution of the puri- 
fied G-proteins with PTX-treated membranes. The control 
InsP3 formation in the membranes pretreated with 10/.tg/mg 
of PTX in the presence of 100 /tM GTP was 136.0 + 16.9 
pmol/mg protein (n = 3), while the reconstitution of purified 
Gil ,  Go or PTX-treated Gil  (0.25-1 pmol/tube) showed no 
significant change in InsP3 formation in the presence o1 GTP. 
As shown in Fig. 3, the reconstitution of purified Gil or Go 
within 1 pmol of each G-protein/tube into PTX-treated mem- 
branes showed no significant change in PLC activity in the 
presence of GTP, being in consistent with other report [4]. 
Under such conditions, U-50,488H at 100 nM inhibited the 
PLC activity in preparations reconstituted with Gi l  at 0.5-1.0 
pmol/tube, to a similar extent (by 87% of control), compared 
to findings in membranes without PTX (Fig. 1A,C,D), but not 
with Go at 0.25-1.0 pmol/tube. When 1 pmol/tube of purified 
Gi l  previously ADP-ribosylated by PTX (10/.tg/ml, 37°C for 
30 min) was reconstituted into PTX-treated membranes, recov- 
ery of the x-agonist-inhibition f PLC was no longer observed. 
4. Discussion 
InsP3 accumulation was stimulated by GTP and its unhydro- 
lyzable analogs, but not by other nucleotides, in guinea pig 
cerebellar membranes. This finding provides the evidence that 
membrane-bound PLC activity is regulated by G-proteins. The 
x-opioid agonist inhibited the GTP-stimulated PLC to the level 
seen without GTP. The involvement of G-proteins in this 
x-agonist-inhibition f PLC is evident from the following ob- 
servations; (i) the inhibition was specific for PLC activity stimu- 
lated by GTP, but not by millimolar Ca >, (ii) the inhibition was 
abolished by pretreatment of membranes with PTX, a com- 
pound which inactivates substrate G-proteins to uncouple to 
receptors in membranes by ADP-ribosylation of their a-sub- 
units [29,30], (iii) the selective recovery from the PTX-inhibition 
of l¢-agonist action was observed by reconstitution with puri- 
fied Gil .  
We have carried out functional reconstitution experiments 
and found that kyotorphin stimulates GTP-stimulated PLC via 
an activation of Gi l  in rat brain membranes [9] and that 
~-opioid receptor mediates PLC activation through Gil  in Xen- 
opus oocytes [10]. Similar findings were reported by Kikuchi 
et al. [4] who demonstrated that fMet-Leu-Phe, a chemotactic 
peptide-stimulation of PLC was abolished by PTX-treatment 
and was recovered by reconstitution with Gi or Go in human 
leukemic (HL-60) cell membranes. These findings trongly sug- 
gest that PTX-substrate G-proteins are functionally coupled to 
PLC in a stimulatory fashion. The fl-type isozymes of various 
PLCs are well known to be regulated by G-protein-coupled 
(metabotropic) receptors. Recent studies have revealed that 
PLCfll is activated by ~-subunit of PTX-insensitive G-protein, 
such as Gq, G11 and G16, PLCfl2 by fl?-subunits which are 
released from many heterotrimeric G-proteins including PTX- 
sensitive ones, and PLCfl3 by both Gq/11 /16~ and fl?'-subunits 
[29]. These findings suggest that fl)'-subunits rather than 
0~-subunits of PTX-sensitive G-proteins may play roles in PLC 
Table 1 
Effects of various nucleotides on 
cerebellar membranes 
InsP3 accumulation i  guinea pig 
Addition InsP3 accumulated 
(%) of control 
No addition 118.0 + 10.4 
GTP 256.5 + 49.7* 
GppNHp 264.4 + 30.5* 
GTP?S 249.6 _+ 10.3" 
GMP 105.6 + 9.7 
GDP 104.9 + 11.8 
CDP 91.6 + 17.7 
CTP 93.8 +- 5.6 
Guinea pig cerebellar membranes were incubated inthe presence of the 
indicated nucleotides at 100 ¢tM at 37°C for 2 rain, as described in 
section 2. Results represent the percentage of control InsP3 amounts 
(42.9 + 5.4 pmol/mg protein, n= 13) without incubation as the S.E.M. 
of the mean from separate 3-9 experiments. *The difference isstatisti- 
cally significant, compared to no addition (P < 0.05, Student's t-test). 
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activation. However, in our recent findings using electrophysi- 
ological detection in Xenopus oocyte, the currents evoked 
through Gi 1-coupled 8-opioid receptor were mediated by over- 
expression of G i la  [11], but not by fly-subunits (H. Ueda, T. 
Miyamae and Y. Misu, unpublished observation). Thus, it may 
be true that G i la  per se is also involved in stimulatory regula- 
tion of PLC activity. However, there is a problem that no effect 
of the purified Gi l  was observed on the activation of PLC in 
the reconstitution experiments. Taken all above-mentioned into 
consideration, such an unexpected finding may be explained by 
the view that the activities of related PLC isozymes are fully 
regulated by G-proteins in vivo, and previously ADP-ribosyl- 
ated G-proteins which retain their intrinsic activity [28], were 
just replaced by excess amounts of exogenously added non- 
ribosylated ones. 
In this context, the inhibition of PTX-substrate G-protein 
(such as Gil) activity is presumably involved in the x-opioid 
receptor-mediated inhibition of PLC in guinea pig cerebellar 
membranes. Indeed, this view was supported by our finding 
that the x-agonist inhibits G-protein activity, determined by 
measuring low-Kin GTPase or GDP-GTP exchange activity due 
to membrane-bound G-proteins in the guinea pig cerebellum 
[15,16]. Thus, such a novel mechanism through an inhibition 
of G-protein activity would be involved in the x-receptor-medi- 
ated inhibition of PLC activity. However, as other components 
in the Gil-mediated PLC activation may be also involved, fur- 
ther detailed experiments using purified (or recombinant) pro- 
teins should be important subjects in future to prove our pro- 
posal. 
Another important question is why the x-agonist almost 
completely inhibited the GTP-stimulated PLC activities in the 
membranes in a PTX-sensitive manner. The PTX-insensitive 
Gq/11/16, are now well known to play important roles in the 
receptor-mediated PLC activation, and parts of GTP-stimu- 
lated PLC activities hould have been attributed to Gq/11/16- 
mediated ones which are activated by GTP per se or through 
unintentionally activated receptors uch as ATP or prosta- 
glandin receptors [30,31] in the present preparations. Such a 
discrepancy, however, may be explained in part by the fact that 
the intrinsic activity of Gq is very weak, compared with PTX- 
sensitive G-proteins, such as Gi and Go [1], and thereby the 
activation of Gq/11/16 by GTP might be limited in such synap- 
tosomal membranes prepared from the guinea pig cerebellum. 
Alternatively it might be explained by the possibility that f ly 
subunits released from Gi or abundant Go activated by GTP 
per se immediately trap the a-subunits released to a small extent 
from Gq/l l /16 by GTP per se or unintentionally activated 
receptors. Indeed, Go is not only most abundantly found in the 
brain among many heterotrimeric G-proteins, but also its in- 
trinsic activity (GTPase or GDP-GTP exchange activity) is the 
highest [32]. Furthermore Goa has no activity to activate PLC 
in the Xenopus oocyte, since evoked currents through 8-opioid 
receptor which is coupled to Go in neuroblastoma X glioma 
hubrid NG108-15 cells [33], were not mediated by overexpres- 
sion of Goa [11]. All these findings suggest that the G-protein 
activated by GTP per se and responsible for such a GTP- 
activated PLC activity is PTX-sensitive G-protein, but not Go 
in Xenopus oocytes. Taking into account he previous findings 
that the x-opioid agonist inhibited the GDP-GTP exchange 
activity of Gil  and Gi2, but not Go which had been reconsti- 
tuted into the similar membranes prepared from the guinea pig 
cerebellum [10], it is very likely such Gil and Gi2 might be 
responsible for the x-receptor-mediated inhibition of PLC 
activity. We have no data about the contribution of Gi3 in 
x-receptor actions. However, as Gi3 known to be coupled to 
c~-opioid receptor [34] failed to show the functional coupling to 
PLC in the Xenopus oocyte expressing c~-receptor [11], it is 
unlikely that Gi3 less abundantly found in the brain [23] plays 
an imporant role in such x-receptor-mediated actions. 
In the present experiments, we observed the x-agonist-inhibi- 
tion of PLC activity stimulated by GTP. As GTP exists in a 
concentration of0.1 ~2.3 mM in the cytosol of various cells [35], 
such a x-receptor-mediated effect might be related to the inhi- 
bition of spontaneous activities of PLC through G-proteins 
(Gi). Another possible role is in the cross-talk with 
metabotropic receptors at the level of G-proteins. There are 
reports that a x-opioid agonist and an a2-adrenoceptor agonist 
showed a mutual antagonism in regulation of intrasynap- 
tosomal free [Ca:+]i [36] or norepinephrine r lease [37]. As the 
x-agonist inhibited [Ca2+]i and a2-receptor is well known to 
couple to Gi in a stimulatory fashion [38], it is plausible that 
a common Gi-PLC system is involved in this antagonism. 
In conclusion, the present study provides the evidence that 
the inhibitory effect of opioid x-agonist on the PLC in guinea 
pig cerebellar membranes is attributed to the mechanisms 
through an inhibitory coupling between the opioid x-receptor 
and PTX-sensitive G-proteins uch as Gil. Such a novel mech- 
anism may be involved in regulation of signaling of many other 
metabotropic receptors through PTX-sensitive G-proteins. 
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